lucky Vector Artist Photographer / Shutterstock.com
The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.
The increasing price of medicines is a controversial and challenging issue worldwide. Countries adopt mechanisms to regulate such prices, generating an assumption that sales within regulated limits are legitimate.
However, on June 7 the Brazilian Federal Prosecutor’s Office (MPF) filed a class action against Roche’s Brazilian subsidiary arguing that its sales of Herceptin (trastuzumab) to state governments involves an alleged abuse of IP rights, even though they are compliant with the price regulatory framework. The abuse, according to the MPF, results from higher prices charged to states in named patient sales in order to comply with court orders, compared to sales to the Ministry of Health (MoH).
This case is of unparalleled relevance for the Brazilian pharmaceutical sector as it challenges a common belief that complying with the requirements of price regulation suffices.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Anderson Ribeiro, Ricardo Campello, Provedel Advogados, MPF, CMED, IP rights abuse claims, MoH, patent, trademark, copyright, Roche,